Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Dermatologic 1

Conditions

Melanoma 35Carcinoma, Non-Small-Cell Lung 11Colorectal Neoplasms 8Carcinoma, Renal Cell 7Neoplasms 6Uveal Melanoma 5Precursor Cell Lymphoblastic Leukemia-Lymphoma 5Neoplasm Metastasis 5Lymphoma, T-Cell, Cutaneous 5Lymphoma, Non-Hodgkin 5Lymphoma, Mantle-Cell 5Lymphoma, Large-Cell, Immunoblastic 5Lymphoma, Large-Cell, Anaplastic 5Lymphoma, Large B-Cell, Diffuse 5Lymphoma, Follicular 5Lymphoma, B-Cell, Marginal Zone 5Leukemia, Lymphocytic, Chronic, B-Cell 5Burkitt Lymphoma 5Waldenstrom Macroglobulinemia 4Stomach Neoplasms 4Squamous Cell Carcinoma of Head and Neck 4Sezary Syndrome 4Pancreatic Neoplasms 4Ovarian Neoplasms 4Mycosis Fungoides 4Intraocular Lymphoma 4Immunoblastic Lymphadenopathy 4Hodgkin Disease 4Carcinoma, Transitional Cell 4Breast Neoplasms 4

Interventions

pembrolizumab 1Temozolomide 1Paclitaxel 1Dacarbazine 1Cisplatin 1Carboplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Advanced Melanoma × Carboplatin × Dermatologic × Clear all
NCT07310784 2026-05-12

A Phase II Trial of LM103 in Advanced Melanoma

Suzhou BlueHorse Therapeutics Co., Ltd.

Phase 2 Recruiting
92 enrolled
Dermatologic

Advanced Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡